dual aurora kinase A/JAK2 inhibitors (H Lee Moffitt Cancer Center and Research Institute)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namedual aurora kinase A/JAK2 inhibitors (H Lee Moffitt Cancer Center and Research Institute)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsSerine/threonine-protein kinase Aurora-A inhibitors
TargetsSerine/threonine-protein kinase Aurora-ATyrosine-protein kinase JAK2
Therapy Area/IndicationsGraft vs Host Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesH Lee Moffitt Cancer Center & Research Institute
Active IndicationsN/A
Inactive IndicationsGraft vs Host Disease

Other Information

ATC CodeN/A
Related LinksN/A